Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is currently positioned as the first-line therapy for unresectable hepatocellular carcinoma (u-HCC). It may be difficult to decide whether to continue this treatment if radiological response is assessed as stable disease (SD). Therefor...

Full description

Bibliographic Details
Main Authors: Takahiro Kinami, Kei Amioka, Tomokazu Kawaoka, Shinsuke Uchikawa, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma (HCC)
atezolizumab plus bevacizumab combination therapy (Atezo + Beva)
alpha-fetoprotein (AFP)
Response Evaluation Criteria in Solid Tumors (RECIST)
overall survival (OS)
progression-free survival (PFS)
Online Access:https://www.mdpi.com/2072-6694/15/8/2304

Internet

https://www.mdpi.com/2072-6694/15/8/2304

Similar Items